NCT01049399

Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112, a GSK-3 Inhibitor, Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 146 (actual)
• Sponsor: Noscira SA · Industry
• Sex: All
• Age: 40 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine wether NP031112 is safe and effective in the treatment of mild to moderate Progressive Supranuclear Palsy

Conditions

• Progressive Supranuclear Palsy

Interventions

Type	Name	Description
DRUG	tideglusib	800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
DRUG	tideglusib	600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
DRUG	placebo	powder for oral suspension administered once daily in fasting conditions for 52 weeks

Timeline

• Start date: 2009-12-01
• Primary completion: 2011-09-01
• Completion: 2011-11-01
• First posted: 2010-01-14
• Last updated: 2012-01-05

Locations

24 sites across 4 countries: United States, Germany, Spain, United Kingdom